Skip to content

Effects of Modified Precision Functional Sphincter-Preserving Surgery (PPS) on Ultralow Rectal Cancer

Effects of Modified Precision Functional Sphincter-Preserving Surgery (PPS) on Ultralow Rectal Cancer: A Multicenter Prospective Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05245565
Enrollment
120
Registered
2022-02-18
Start date
2021-05-01
Completion date
2026-05-01
Last updated
2023-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Faecal Incontinence, Leakage, Anastomotic, Rectum Cancer, Stoma Colostomy

Brief summary

RATIONALE: Colorectal cancer is one of the most common cancers. However, approaches to minimize surgical trauma, preserve anal function, avoid abdominal stoma, and improve quality of life for patients with ultralow rectal cancers were limited. Thus, new technologies are urgently needed to improve the anal preservation rate, reduce the incidence of anastomotic leakage and improve postoperative anal function in patients with ultralow rectal cancer. PURPOSE: This one-arm multicenter prospective cohort study aims to collect the data of patients with ultralow rectal cancer who undergo sphincter-preserving surgeries, including modified PPS and conventional surgeries, then compare the effects of different operations on clinical outcomes and to see the efficacy and safety of modified PPS surgery when compared with conventional procedures in the treatment of ultralow rectal cancer.

Interventions

None listed

Sponsors

Shanghai 10th People's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Histological proof of newly diagnosed primary adenocarcinoma of the rectum 2. The lower edge of tumor \< 3 cm from the dentate line 3. Clinical T stage ≤ T3

Exclusion criteria

1. The lower edge of tumor \< 1 cm from the dentate line 2. Locally advanced stage of tumor 3. Presence of metastatic disease or recurrent rectal tumor 4. Concomitant malignancies 5. Concurrent uncontrolled medical conditions 6. Impaired anal function before surgery 7. Presence of acute bowel obstruction or bowel perforation caused by cancer 8. Pregnancy or breast feeding

Design outcomes

Primary

MeasureTime frameDescription
Rate of temporary defunctioning stomaWithin 30 days after operationThe percentage of patients who get temporary defunctioning stoma to limit the consequences of anastomotic leakage.
The percentage of patients who develop anastomotic leakageWithin 30 days after operationThe percentage of patients who develop anastomotic leakage
Postoperative anal function assessed by Wexner scale2 years since the start of treatmentRanging from 0 (perfect continence) to 20 (complete incontinence)
Postoperative anal function assessed by Vaizey scale2 years since the start of treatmentRanging from 0 (perfect continence) to 24 (complete incontinence)

Secondary

MeasureTime frameDescription
30-Day Readmission RateWithin 30 days after operationPercentage of readmitted patients within 30 days after operation
Rate of sphincter-preservation ratesWithin 30 days after operationThe percentage of patients who preserve the anatomical structure of the anus
Overall survivalUp to 5 years after the last patient recruitedOverall survival is defined as the time from surgery until death from any cause.
Disease-free survivalUp to 5 years after the last patient recruitedDisease-free survival is defined as the time from surgery to recurrence of tumor or death
The number of short-term postoperative complicationsWithin 30 days after operationThe number of grade II and higher postoperative complications according to the Clavien-Dindo classification
Postoperative hospital stayWithin 30 days after operationThe time between the operation date and the discharge date.
Hospitalization costsWithin 30 days after operationThe total cost of hospitalization

Countries

China

Contacts

Primary ContactCheng-Le Zhuang, MD, PhD
zhuangchengle@tongji.edu.cn+86-19921618250

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026